Abstract-Familial hypobetalipoproteinemia (FHBL) is an autosomal codominant disorder characterized by low levels of apolipoprotein (apo) B and low-density lipoprotein (LDL) cholesterol. Decreased production rates of apoB have been demonstrated in vivo in FHBL heterozygotes. In the present study, we wished to investigate whether the transport of triglycerides was similarly affected in these subjects. Therefore, we studied the in vivo kinetics of very-low-density lipoprotein (VLDL) triglycerides and VLDL apoB-100 simultaneously in 7 FHBL heterozygotes from 2 wellcharacterized kindreds and 7 healthy normolipidemic subjects. In both kindreds, hypobetalipoproteinemia is caused by mutations in the 5Ј portion of the apoB gene specifying short truncations of apoB undetectable in plasma. A bolus injection of deuterated palmitate and a primed constant infusion of deuterated leucine were given simultaneously, and their incorporation into VLDL triglycerides and VLDL apoB, respectively, were determined by gas chromatographymass spectrometry. Kinetic parameters were calculated by using compartmental modeling. VLDL apoB fractional catabolic rates (FCRs) in FHBL heterozygotes and controls were similar (11.6Ϯ3.9 and 10.9Ϯ2.4 pools per day, respectively, Pϭ0.72). On the other hand, FHBL heterozygotes had a 75% decrease in VLDL apoB production rates compared with normal subjects (5.8Ϯ1.8 versus 23.4Ϯ7.1 mg/kg per day, PϽ0.001). The decreased production rates of VLDL apoB accounts for the very low concentrations of plasma apoB found in heterozygotes from these kindreds (24% of normal Key Words: familial hypobetalipoproteinemia Ⅲ apolipoprotein B Ⅲ triglycerides Ⅲ stable isotopes F amilial hypobetalipoproteinemia (FHBL) is an autosomal codominant disorder characterized by abnormally low plasma levels of apoB and LDL cholesterol. Heterozygotes are usually asymptomatic, whereas homozygotes may manifest signs of fat malabsorption and complications related to deficiency of fat-soluble vitamins. 1 Some forms of FHBL are caused by mutations in the apoB gene on chromosome 2, which interfere with the translation of the full-length protein and produce truncated forms of apoB detectable in plasma. 1,2 The truncations are designated according to a centile nomenclature using the full-length apoB, consisting of 4536 amino acids as apoB-100. In FHBL heterozygotes with mutations in the 5Ј region of the apoB gene predicted to produce truncations shorter than apoB-27, no truncated apoB forms are detectable in plasma. It is assumed that this is due to failure of these short truncations in the assembly and secretion of triglyceride-rich lipoproteins. Four such mutations have been identified to date. [3] [4] [5] To define the mechanisms responsible for the decreased plasma apoB levels in FHBL heterozygotes, our group and others used stable isotope tracer methodology to study the in vivo kinetics of apoB. These studies have demonstrated that the truncated apoB forms were produced at lower rates than were the normal apoB-100 forms. 6, 7 The clearance of some truncations from plasma, especially those containing the LDL receptor-binding domain (ie, apoB-75 and apoB-89), was faster than apoB-100 clearance, as reflected by higher fractional catabolic rates (FCRs). 8,9 FHBL heterozygotes also produce apoB-100 at a production rate that is less than the 50% of normal expected from the presence of one normal allele, 10,11 further contributing to the low plasma apoB levels.
F amilial hypobetalipoproteinemia (FHBL) is an autosomal codominant disorder characterized by abnormally low plasma levels of apoB and LDL cholesterol. Heterozygotes are usually asymptomatic, whereas homozygotes may manifest signs of fat malabsorption and complications related to deficiency of fat-soluble vitamins. 1 Some forms of FHBL are caused by mutations in the apoB gene on chromosome 2, which interfere with the translation of the full-length protein and produce truncated forms of apoB detectable in plasma. 1, 2 The truncations are designated according to a centile nomenclature using the full-length apoB, consisting of 4536 amino acids as apoB-100. In FHBL heterozygotes with mutations in the 5Ј region of the apoB gene predicted to produce truncations shorter than apoB-27, no truncated apoB forms are detectable in plasma. It is assumed that this is due to failure of these short truncations in the assembly and secretion of triglyceride-rich lipoproteins. Four such mutations have been identified to date. [3] [4] [5] To define the mechanisms responsible for the decreased plasma apoB levels in FHBL heterozygotes, our group and others used stable isotope tracer methodology to study the in vivo kinetics of apoB. These studies have demonstrated that the truncated apoB forms were produced at lower rates than were the normal apoB-100 forms. 6, 7 The clearance of some truncations from plasma, especially those containing the LDL receptor-binding domain (ie, apoB-75 and apoB-89), was faster than apoB-100 clearance, as reflected by higher fractional catabolic rates (FCRs). 8, 9 FHBL heterozygotes also produce apoB-100 at a production rate that is less than the 50% of normal expected from the presence of one normal allele, 10, 11 further contributing to the low plasma apoB levels.
ApoB-100 is secreted from the liver in VLDL particles associated with lipids, mainly triglycerides, which serve as an important source of energy delivery to peripheral tissues in the form of fatty acids. 12 It is unknown to what extent the hepatic secretion of triglycerides is affected by the defect in apoB secretion observed in FHBL heterozygotes. The secretion of apoB and triglycerides is associated in some hypertriglyceridemic states. 13 However, dissociation of VLDL apoB and triglyceride secretion rates has been reported in other conditions, 14, 15 resulting in VLDL particles with variable triglyceride to apoB ratios. A marked reduction in VLDL triglyceride export would limit the delivery of fatty acids to peripheral tissues, which would result in accumulation of triglycerides in hepatocytes and could eventually lead to the development of fatty liver. Because FHBL heterozygotes are usually asymptomatic and in a good nutritional state, we hypothesized that the production of VLDL triglycerides may not be affected to the same extent as apoB production in these subjects. To test this hypothesis, we evaluated the in vivo metabolism of VLDL triglyceride and VLDL apoB simultaneously in FHBL heterozygotes from 2 well-characterized FHBL kindreds. We have previously described the genetic defects responsible for hypobetalipoproteinemia in both kindreds. 16, 17 The affected members of the C kindred have a non-sense mutation (Arg4123stop) in exon 10 of the apoB gene, which is predicted to produce apoB-9. In the D kindred, a mutation in the splice donor site in intron 5 of the apoB gene expected to produce apoB-2 was found in affected subjects. We could not find the truncated protein in plasma in heterozygotes from these 2 kindreds, and their VLDL particles contain only apoB-100 produced by the normal allele.
In the present study, we used a novel approach for studying the in vivo kinetics of VLDL triglycerides and apoB simultaneously: endogenous labeling with stable isotopically labeled tracers. Deuterated palmitate and deuterated leucine were infused, and their incorporation into VLDL triglycerides and VLDL apoB, respectively, were determined. The data were analyzed by compartmental modeling to determine the kinetic parameters.
Methods

Subjects
Three heterozygotes from the C kindred, 4 heterozygotes from the D kindred, and 7 normal healthy controls participated in the present study. The clinical characteristics of the study subjects are shown in Table 1 . All FHBL heterozygotes were asymptomatic and taking no medications. The subjects in the control group were all normolipidemic, had no evidence of hepatic, renal, or endocrine disorders, and were not taking any medications. Detailed physical examinations, blood counts, liver function tests, and lipid profiles were performed on enrollment. All participants gave written informed consent.
Study Protocol
The study protocol was approved by the Human Studies Committee of Washington University School of Medicine. The subjects were instructed not to change their diet 10 days before the study. For the kinetic study, subjects were admitted to the General Clinical Research Center after a 10-hour fast. An intravenous catheter was inserted into the antecubital vein of one arm for the infusion of tracers, and a second catheter was inserted into a vein in the other arm for blood sampling. A bolus of [ 2 H 2 ]palmitate (potassium salt, 98% isotopic purity, Isotec) complexed to 5% human albumin at a dose of 6 mol/kg was injected over 1 minute, immediately followed by a primed constant infusion of deuterated leucine. [ 2 H 3 ]Leucine (98% isotopic purity, Cambridge Isotopes) was administered as a priming dose of 6.3 mol/kg, followed by 6.3 mol/kg per hour for 8 hours through a calibrated syringe pump (Harvard Apparatus). The subjects remained fasting during the infusion period and for another 8 hours after the termination of the infusion. Noncaloric drinks were permitted throughout the study. A total of 21 blood samples for leucine and palmitate enrichment measurements were drawn during the study, starting at time 0 and continuing up to 96 hours. Blood was collected into EDTA-containing tubes, and plasma was separated immediately by low-speed centrifugation.
Analytical Methods
Measurements of Plasma Lipids and Apolipoproteins
By use of commercially available enzymatic kits (Technicon Instruments), total cholesterol, triglycerides, LDL cholesterol, and HDL cholesterol were determined on baseline plasma samples by the Lipid Research Center Core Laboratory at Washington University School of Medicine. Plasma apoB and apoA-I were determined by immunonephelometry (Behring).
Isolation of VLDL
VLDL (dϽ1.006 g/mL) was isolated from 5 mL of fresh plasma by ultracentrifugation at 40 000 rpm for 18 hours and stored at -70°C until further analysis. Triglyceride and cholesterol concentrations in VLDL fractions were determined by enzymatic assays. VLDL apoB concentrations were determined by enzyme-linked immunosorbent assay 7,10 using the monoclonal antibody C1.4.
Isolation of VLDL ApoB and Plasma Amino Acids
ApoB was isolated from VLDL fractions by precipitation with butanol isopropyl ether 18 and hydrolyzed in 6N HCl for 24 hours at 110°C. Amino acids were isolated from 0.25 mL of plasma by cation exchange chromatography. 19 The amino acids obtained from apoB hydrolysates and plasma amino acids were derivatized to n-heptafluorobutyryl-n-propyl esters and dissolved in ethyl acetate for enrichment measurements. 20 Leucine enrichment was determined by negative chemical ionization gas chromatography-mass spectrometry on a Hewlett-Packard model 5988 equipped with a DB-17 capillary column. Molecular ions at mass-to-charge ratio (m/z) 349 (mϩ0) and 352 (mϩ3) were selectively monitored. The enrichment data were converted to tracer/tracee ratio (TTR) by analysis of isotopic enrichment standards.
Isolation of VLDL Triglycerides and Plasma Free Fatty Acids
Lipids were extracted from VLDL fractions by chloroform-methanol (1:2 [vol/vol]) and separated by thin-layer chromatographic plates (Whatman Inc). Triglyceride bands were scraped from the plates, derivatized with acetyl chloride-methanol (1:20 [vol/vol]) at 70°C for 30 minutes, and the resulting methyl esters were extracted with heptane. Lipids were extracted from 0.25 mL plasma by hexane, reacted with iodomethane (dissolved in dichloromethane 1:10 [vol/vol]) to convert free fatty acids (FFAs) to their methyl esters, and then passed onto solid-phase extraction cartridges (Lc-Si SPE Tubes, Supelco). Methyl esters were eluted from the cartridges with 2% ethyl acetate in hexane. 21 The samples were dried under N 2 and dissolved in heptane for enrichment measurements.
Methyl palmitate enrichment in VLDL triglycerides and plasma was determined by electron impact ionization gas chromatographymass spectrometry on a Hewlett-Packard model 5971 MSD equipped with an Omegawax 250 capillary column. Molecular ions at m/z 270 (mϩ0) and 272 (mϩ2) were selectively monitored. Isotopic enrichment standards were used as previously described, 21 and the data were expressed as TTR.
For determination of plasma FFA concentrations, heptadecanoic acid was added as an internal standard to 4 plasma samples (time points 0, 4, 8, and 16 hours) from each study. Plasma FFAs were derivatized and extracted as described above and analyzed by gas chromatography. The mean of the 4 values was used to describe plasma FFA concentrations.
Kinetic Analysis
VLDL apoB and VLDL triglyceride kinetics were analyzed by compartmental modeling using the SAAM II program (SAAM Institute, University of Washington, Seattle). Several assumptions were made that are common to all linear, time-invariant compartmental models as used in the present study. It is assumed that transfer of material between compartments follows first-order kinetics with respect to tracer content, which is always a valid assumption when the tracer does not perturb the pool size, 22 as for apoB and triglycerides. It is also assumed that the rate constants do not vary with time, such that the system is at metabolic steady state. The model structure represents the minimal complexity that is necessary and sufficient to describe the kinetic data.
The model used for apoB kinetics ( Figure 1 ) has been used previously to describe VLDL apoB kinetics for apoB-100 and various truncated forms of apoB. 6 -10,23 The model consists of (1) a forcing function to describe plasma leucine enrichment during and after the termination of the 8-hour primed continuous tracer infusion period, (2) a delay for hepatic VLDL apoB synthesis, assembly, and secretion, and (3) a homogeneous VLDL apoB compartment. It was not necessary to postulate the presence of "fast" and "slow" VLDL compartments for any subject in the present study.
The model used for VLDL triglyceride kinetics is structurally similar to that used for apoB (Figure 1) . In preliminary analyses, it was determined that a sum of 3 exponential terms was necessary and sufficient to describe the bolus plasma [ 2 H 2 ]palmitate kinetics. Therefore, a 3-compartment catenary model structure was arbitrarily chosen for this purpose; a 3-compartment mammillary model or a "forcing function" defined as a sum of 3 exponentials would have provided identical descriptions of plasma palmitate kinetics. Since the focus of the present study involves the turnover of VLDL triglycerides, the model structure used to define plasma palmitate kinetics is irrelevant. After a delay for VLDL synthesis and secretion, the [ 2 H 2 ] palmitate appeared in VLDL triglycerides. As for apoB, it was not necessary to postulate the existence of heterogeneous "fast" and "slow" VLDL compartments to account for the VLDL triglyceride palmitate kinetics, nor was it necessary to postulate the existence of a second "slow" biosynthetic pathway to provide a source of intrahepatically recycled tracer. 24 VLDL apoB and VLDL triglyceride production rates were calculated as the product of their respective FCRs and pool sizes, assuming a plasma volume 0.045 L/kg.
Statistical Analysis
Data are presented as meanϮSD. Unpaired t tests were used to compare results obtained in control subjects and FHBL heterozygotes. The Pearson correlation coefficient was used to analyze the correlation between apoB and triglyceride parameters. A value of PϽ0.05 was considered to be significant.
Results
Lipid and Apo Levels
The subjects in the control group and the FHBL subjects were well matched for sex, age, and body mass index (Table 1) . By BMI indicates body mass index; TC, total cholesterol; and LDL-C and HDL-C, LDL and HDL cholesterol, respectively. FHBL subjects 1 to 3 are affected members of the C kindred; FHBL subjects 4 to 7 are affected members of the D kindred.
definition, plasma levels of total cholesterol, LDL cholesterol, triglycerides, and apoB were significantly lower in FHBL heterozygotes than in controls (PϽ0.001 for all parameters). There were no differences in mean plasma HDL cholesterol and apoA1 levels between the 2 groups ( Table 1) . Plasma total FFA concentrations were lower in FHBL heterozygotes than in controls (0.55Ϯ0.14 versus 0.72Ϯ0.15 mmol/L, Pϭ0.04).
Levels of VLDL apoB and VLDL triglycerides were determined at 4 different time points during each study. The coefficients of variation for both apoB and triglycerides were Ͻ10% between different samples, indicating that each subject remained in a steady state throughout the kinetic study. The concentrations of VLDL triglycerides, VLDL cholesterol, and VLDL apoB were significantly lower in FHBL heterozygotes than in control subjects (PՅ0.01 for all variables). The mean ratio of triglyceride to apoB concentrations in VLDL fractions was higher in FHBL subjects than in normal controls, although the difference was not statistically significant (16.9Ϯ4.9 versus 12.1Ϯ4.8, Pϭ0.09) ( Table 2 ).
Kinetic Parameters
Plasma and VLDL apoB leucine TTR curves from 2 representative studies are shown in Figure 2 . As the figure shows, there was a good agreement between the observed tracer data and the model-derived fits for VLDL apoB. Mean VLDL apoB FCRs were not significantly different between the FHBL and control subjects (11.6Ϯ3.9 versus 10.9Ϯ2.4 pools per day, Pϭ0.72), whereas the mean production rate of VLDL apoB in FHBL heterozygotes was 24.8% of that in control subjects (5.8Ϯ1.8 versus 23.4Ϯ7.1 mg/kg per day, PϽ0.001) ( Table 3 ). The decreased production rates account for the 75% reduction in VLDL apoB pool size observed in FHBL subjects. Figure 3 shows plasma and VLDL triglyceride palmitate TTR curves from 2 representative studies. In all subjects, the enrichment of palmitate in VLDL trigycerides reached a peak at 60 to 90 minutes after the bolus injection was given. As was observed for apoB, there was a good agreement between the observed tracer data and the model-derived fits. No significant difference in VLDL triglyceride FCRs was observed between FHBL heterozygotes and normal subjects (1.06Ϯ0.74 versus 0.89Ϯ0.50 pools per hour, Pϭ0.61). On Figure 2 . TTRs of leucine in plasma (E) and VLDL apoB (F) in subject 5 of the control group (A) and subject 6 of FHBL heterozygotes (B) (see Table 1 for characterization of the subjects). Symbols represent observed values, and solid lines represent model-derived fits for VLDL apoB. 
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the other hand, the production rates of VLDL triglycerides were significantly lower in the FHBL heterozygotes than in the normal controls (9.3Ϯ6.0 versus 23.0Ϯ9.6 mol/kg per hour, Pϭ0.008) ( Table 4) . Most of the reduction in VLDL triglyceride pool size could be attributed to the decrease in production rates. However, the decrease in VLDL triglyceride production rates in FHBL subjects (59.6%) was less pronounced than the decrease in VLDL apoB production rates (75.2%).
There was a good correlation between the FCRs of VLDL apoB and VLDL triglycerides in the study subjects, as shown in Figure 4 (rϭ0.84, PϽ0.001) . The positive significant correlation persisted when the FCRs of FHBL heterozygotes and controls were analyzed separately. The correlation between VLDL apoB and VLDL triglyceride production rates was relatively weaker (rϭ0.58, Pϭ0.03) ( Figure 5 ). No significant correlation was observed when the production rates of each study group were analyzed separately (rϭ0.42, PϭNS for FHBL subjects; rϭ0.11, PϭNS for controls).
Discussion
In the present study, we wished to evaluate whether the secretion rates of VLDL apoB and VLDL triglycerides were associated in FHBL heterozygotes and to what extent triglyceride transport was affected in these subjects. Therefore, we investigated simultaneously the in vivo metabolism of the triglyceride and apoB moieties of VLDL in FHBL heterozygotes. The studies were performed in affected members of 2 families with well-characterized mutations in the apoB gene on chromosome 2. Both mutations give rise to truncated apoB forms that are not detectable in plasma because of their location in the 5Ј region of the apoB gene. Hence, affected members have only one functioning allele and only apoB-100 -containing VLDL particles. Our results show that in these FHBL heterozygotes the production rates of VLDL apoB-100 are Ϸ25% of normal, whereas the production rates of triglycerides are Ϸ40% of normal. On the other hand, the catabolism of these 2 VLDL constituents is not altered in FHBL heterozygotes. We have used a novel approach of simultaneous endogenous labeling of VLDL apoB and triglycerides with stable isotope tracers. Stable isotopically labeled leucine has been widely used in the last decade by us 6 -10,23 and others 11, 25, 26 to study the in vivo metabolism of apoB-100 and various truncated forms of apoB, and compartmental models have been developed to calculate the kinetic parameters of the different apoB-containing lipoproteins. On the other hand, the use of stable isotopically labeled precursors of triglycerides is a relatively new tool in kinetic research. Traditionally, studies of in vivo triglyceride metabolism involved the infusion of radiolabeled precursors such as 31 have used mass isotopomer distribution analysis for the measurement of total VLDL triglyceride production rates. They measured the incorporation of [
13 C]acetate into newly synthesized VLDL fatty acids during a 10-hour infusion of the former. This approach obviates the need for measurement of the precursor pool enrichment. However, it should be borne in mind that this method generates data that depend on de novo synthesis of VLDL triglyceride fatty acids and that in conditions with minimal de novo lipogenesis (ie, fasting state) the measured enrichments can be too low to allow a reliable analysis. The use of stable isotopically labeled precursors that incorporate directly into VLDL triglycerides such as palmitate and glycerol may be advantageous in these settings. We have recently conducted a study comparing the use of deuterated palmitate and deuterated glycerol for the study of VLDL triglyceride kinetics in normal volunteers and found that the kinetic parameters obtained with the 2 tracers were not significantly different (B.W. Patterson, N. Elias, S. Klein, unpublished data, 1999) .
One interesting finding in the present study was that VLDL apoB-100 production rates in FHBL heterozygotes were only Ϸ25% of normal, lower than would be expected from the presence of one functioning allele. This is in accordance with previous studies performed both under fasting conditions and in the fed state in FHBL subjects heterozygous for other apoB truncations. Aguilar-Salinas et al 10 have studied the kinetics of apoB-100 in FHBL heterozygotes with 5 different truncations ranging from apoB-31 to apoB-89 and found that VLDL apoB-100 production rates were Ϸ35% of those observed in normal controls closely matched for age, sex, and weight. Welty et al 11 have found that VLDL apoB-100 production rates, determined with subjects in the fed state, were 26% of normal in apoB-67/apoB-100 heterozygotes. The cellular mechanisms underlying the decreased VLDL apoB-100 production rates in FHBL heterozygotes are not fully understood. ApoB-100 secretion studied in vitro in hepatoma cell lines and rat hepatocytes appears to be under posttranscrptional regulation. 32, 33 The amount secreted is determined by the partitioning of newly synthesized apoB-100 between degradation in the endoplasmic reticulum and progression to secretory pathways. Theoretically, the presence of abnormal truncated apoB forms within the hepatocyte may interfere with these processes, leading to increased intracellular degradation and decreased secretion of apoB-100. This is supported by the findings of a recent study in HepG2 cells, which were genetically modified to express apoB-82 in addition to the naturally occurring apoB-100. A greater extent of presecretory degradation of newly synthesized apoB-100 was demonstrated in these cells compared with normal "wildtype" cells, which led to lower than expected secretion of apoB-100. 34 Although there is still no evidence that intracellular degradation plays a major role in the regulation of apoB secretion in humans, these in vitro observations are in accordance with our in vivo findings. The decreased production rates explain the very low plasma apoB concentrations in affected members of these 2 families, which were 24% of those found in normal controls. The clearance of the apoB-100 -containing VLDL particles by the lipolytic pathway or receptor-dependent uptake seems to be unaffected, as reflected by normal VLDL apoB FCRs.
The hepatic secretion of VLDL triglycerides was decreased in our FHBL heterozygotes but to a lesser extent than VLDL apoB secretion, the latter being the factor determining the number of VLDL particles secreted by the liver. Thus, the particles secreted in FHBL heterozygotes are relatively enriched with triglycerides. The ability of the liver to secrete VLDL particles with different triglyceride content under different conditions has been established in previous studies. 35 In vitro observations in rat hepatocyte cell lines led to the hypothesis that the assembly of VLDL proceeds in 2 steps, the first of which involves the synthesis of a lipid-poor apoB-containing particle. In the second step, there is a fusion of this particle with a preformed apoB-free lipid core (synthesized in the smooth endoplasmic reticulum) to become a mature VLDL particle. 36 -38 Recently, Hamilton et al, 39 studying genetically modified mice lacking apoB in intestinal cells, have shown by electron microscopy that these lipid cores can grow larger in the absence of apoB. They hypothesized that the larger size of these particles is due to a retarded rate of transport through the endoplasmic reticular compartment as a consequence of apoB deficiency, which allows them to accumulate more lipids. It is possible that in FHBL heterozygotes with sparse amounts of apoB in hepatocytes, the amount of lipid added to the core particles is higher than usual. Some of these particles would then fuse with lipid-poor apoB particles to produce triglyceride-enriched VLDL. However, any supporting evidence that these processes play a role in VLDL assembly in vivo is still lacking.
Although there appears to be some compensation in triglyceride secretion by the liver, the rates are still reduced by 60% in FHBL heterozygotes compared with normal subjects. This defect in triglyceride export may lead to accumulation of triglycerides in hepatocytes and raises a question about the occurrence of fatty liver in these subjects. There is little information concerning the prevalence of fatty liver in FHBL heterozygotes. In a search of the literature, we could find only one case report of fatty liver in an FHBL heterozygote with well-documented apoB truncation (apoB-38.9). 40 In 2 other reported cases of fatty liver associated with hypocholesterolemia, the diagnosis of FHBL was suspected, but no apoB truncations were found. 41, 42 The occurrence of fatty liver in FHBL depends on the balance between hepatic triglyceride synthetic rates and VLDL triglyceride secretion rates; in other words, it depends on what proportion of triglyceride synthesized can be exported from the liver in VLDL particles. Hepatic triglyceride synthesis is controlled by nutritional and hormonal factors and depends largely on the supply of fatty acids to the liver. These originate from 3 main sources: plasma FFA, hydrolysis of lipoproteins, and de novo lipogenesis. 12 Although we found a modest decrease in plasma FFA concentrations in our FHBL heterozygotes compared with normal controls, the levels were still within normal limits. It will not be feasible to assess hepatic triglyceride synthetic rates in human subjects by in vivo metabolic studies. Animal models of FHBL and in vitro studies in genetically modified cultured hepatocytes may prove to be useful in testing this point.
